ArticleDer Urologe. Ausg. A2014
[Cross-sectional analysis of routine treatment for prostate cancer patients: CAPRIS - a healthcare research project of the IQUO].
Article in Der Urologe. Ausg. A, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDifferent practices for the treatment of prostate cancer patients exist in Germany.
objectivesThe aim of this analysis was to investigate current practice for the treatment of patients with prostate cancer in urological IQUO partner practices (Interest Group for Quality Assurance in the Work of Office-based Uro-oncologists in Germany) dependent on tumor stage and risk factors. The analysis focused on T1/T2 and T3/T4 patients. In addition, applied therapies were analyzed based on risk group classification (CAPRIS, cancer of the prostate identification screening). MATERIALS AND
methodsThis retrospective cross-sectional analysis includes 1000 patients with prostate cancer with at least 12 months of documentation from the OnkoDataMed (ODM) database between February 2008 and May 2012. The 122 IQUO medical practices included were randomly selected; maximally 50 patients per practice were included in the analysis. The database was analyzed in terms of localized T1/T2 tumors and advanced T3/T4 tumors. Risk groups were formed according to parameters of the initial diagnosis including PSA value, tumor stage, and Gleason score. Descriptive statistics were performed to analyze all parameters. RESULTS AND
conclusionsAs expected, PSA is the critical parameter for follow-up and therapy monitoring. Newer therapeutic options have only been initiated to a limited extent. Differentiated risk assessment has not been sufficiently used; however, it does provide a good opportunity for more individualized therapy in the future.
Indexed as
Identifiers
24903838What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.